Valeo Pharma announces its Onstryv product receives public reimbursement in Quebec
News release
by
Valeo Pharma Inc.
Vancouver
|
February 09, 2023 02:03 PM Eastern Standard Time
Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has obtained public reimbursement from the Quebec Government for its product Onstryv (safinamide).
Saviuk told Proactive Health Canada approved Onstryv as an add-on therapy for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Contact Details
Proactive Canada
+1 604-688-8158
